PCM
NTLA icon

Piermont Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Piermont Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-61,620
Closed -$1.3M – 256
2018
Q1 		$1.3M Buy
+61,620
New +$1.52M 0.43% 106

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Piermont Capital Management's NTLA Position: Q2 2018 in Review

Piermont Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2018, closing a stake of 61,620 shares — an estimated $1.3M sold.

Piermont Capital Management first reported a position in NTLA in Q1 2018 and held it in 1 quarter. The position peaked at $1.3M in Q1 2018. 156 funds tracked by Wall St. Rank hold NTLA as of Q2 2018.

  • Piermont Capital Management reported no remaining Intellia Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Piermont Capital Management sold 61,620 Intellia Therapeutics shares in Q2 2018, an estimated $1.3M.
  • Piermont Capital Management first reported a position in Intellia Therapeutics in Q1 2018 and held it in 1 quarter.
  • Piermont Capital Management's Intellia Therapeutics position peaked at $1.3M in Q1 2018.
  • 156 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2018.

Based on Piermont Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.